A Study to Evaluate the Safety and Immunogenicity of EV71 Vaccine

Inclusion Criteria: * Subject who is free of obvious health problems * Able and willing to comply with the study procedure adn give written informed consent Exclusion Criteria: * Female who is pregnant/lactating or planning to be pregnant * Body mass index(BMI) \> 35 * Oral temperature \> 37.5 Celsius at the time of planned vaccination * Subject with any abnormal laboratory results at screening * With a history of herpangina, hand-foot-mouth disease, acute hemorrhagic conjunctivitis or acute gastrointestinal illness associated with enterovirus infection in the past 3 months * Has been diagnosed with neurological, pulmonary, cardiovascular, hematological, hepatic or renal disorder * With a history of hypersensitivity to vaccine or allergic disease * Use of any investigational/non-registered product within 30 days prior to vaccination * Use of immunoglobulins or any blood products within 3 months prior to vaccination * Chronic administration of immunosuppressants or other immunomodulators within 5 months prior to vaccination